Importance of Myeloid Derived Suppressor Cells in Cancer from a Biomarker Perspective

Overview

Journal Cell Immunol

Publisher Elsevier

Specialties Allergy & Immunology
Cell Biology

Date 2021 Jan 14

PMID 33445053

Citations 15

Authors

Suresh Gopi Kalathil

Yasmin Thanavala

Affiliations

Soon will be listed here.

Abstract

Myeloid derived suppressor cells (MDSC) are a heterogenous population of immature myeloid cells that accumulate in tumor bearing host and migrate to lymphoid organs and tumor tissues. This process is controlled by a set of defined pro-inflammatory cytokines and chemokines, which are upregulated in malignancies. MDSC have strong immunosuppressive potential and constitute a major component of the tumor microenvironment (TME). Tumor cells take advantage of the suppressive mechanisms of MDSC to establish an immunosuppressive TME which inhibits antitumor immune responses thereby promoting cancer progression. An immunosuppressive TME acts as a significant barrier to immunotherapeutic interventions. Pre-clinical and clinical studies have demonstrated that enrichment and activation of MDSC is correlated with tumor progression, recurrence and metastasis. In this review we discuss the potential impact of MDSC on tumor progression and its role as a biomarker of prognostic significance in cancer with a special focus on hepatocellular cancer (HCC).

Citing Articles

Crucial role of dendritic cells in the generation of anti-tumor T-cell responses and immunogenic tumor microenvironment to suppress tumor development.

Tominaga M, Uto T, Fukaya T, Mitoma S, Riethmacher D, Umekita K Front Immunol. 2024; 15:1200461.

PMID: 39206204 PMC: 11349553. DOI: 10.3389/fimmu.2024.1200461.

Fibroblast activation protein constitutes a novel target of chimeric antigen receptor T-cell therapy in solid tumors.

Meng S, Hara T, Miura Y, Ishii H Cancer Sci. 2024; 115(11):3532-3542.

PMID: 39169645 PMC: 11531970. DOI: 10.1111/cas.16285.

Mechanisms of myeloid-derived suppressor cell-mediated immunosuppression in colorectal cancer and related therapies.

Nie S, Jing Y, Lu L, Ren S, Ji G, Xu H World J Gastrointest Oncol. 2024; 16(5):1690-1704.

PMID: 38764816 PMC: 11099432. DOI: 10.4251/wjgo.v16.i5.1690.

TGF-β, IL-1β, IL-6 levels and TGF-β/Smad pathway reactivity regulate the link between allergic diseases, cancer risk, and metabolic dysregulations.

Elkoshi Z Front Immunol. 2024; 15:1371753.

PMID: 38629073 PMC: 11019030. DOI: 10.3389/fimmu.2024.1371753.

IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone.

Kast R Oncoscience. 2024; 11:15-31.

PMID: 38524376 PMC: 10959018. DOI: 10.18632/oncoscience.594.

References

Marvel D, Gabrilovich D . Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015; 125(9):3356-64. PMC: 4588239. DOI: 10.1172/JCI80005. View

Kim K, Sim N, Chang J, Kim Y . Tumor immune microenvironment in cancer patients with leukocytosis. Cancer Immunol Immunother. 2020; 69(7):1265-1277. PMC: 11027728. DOI: 10.1007/s00262-020-02545-4. View

Chew V, Lai L, Pan L, Lim C, Li J, Ong R . Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017; 114(29):E5900-E5909. PMC: 5530700. DOI: 10.1073/pnas.1706559114. View

Bruno A, Mortara L, Baci D, Noonan D, Albini A . Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression. Front Immunol. 2019; 10:771. PMC: 6482162. DOI: 10.3389/fimmu.2019.00771. View

Hassel J, Jiang H, Bender C, Winkler J, Sevko A, Shevchenko I . Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe). Oncoimmunology. 2017; 6(9):e1326440. PMC: 5599085. DOI: 10.1080/2162402X.2017.1326440. View

Hsieh C, Hung C, Chiang M, Tsai Y, He J . Hepatic Stellate Cells Enhance Liver Cancer Progression by Inducing Myeloid-Derived Suppressor Cells through Interleukin-6 Signaling. Int J Mol Sci. 2019; 20(20). PMC: 6834132. DOI: 10.3390/ijms20205079. View

Choi J, Sun E, Cho S . IL-12 Enhances Immune Response by Modulation of Myeloid Derived Suppressor Cells in Tumor Microenvironment. Chonnam Med J. 2019; 55(1):31-39. PMC: 6351325. DOI: 10.4068/cmj.2019.55.1.31. View

Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J . Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One. 2013; 8(2):e57114. PMC: 3577767. DOI: 10.1371/journal.pone.0057114. View

Eruslanov E, Neuberger M, Daurkin I, Perrin G, Algood C, Dahm P . Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer. 2011; 130(5):1109-19. DOI: 10.1002/ijc.26123. View

10.

Eriksson E, Wenthe J, Irenaeus S, Loskog A, Ullenhag G . Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. J Transl Med. 2016; 14(1):282. PMC: 5041438. DOI: 10.1186/s12967-016-1037-z. View

11.

Yang Z, Guo J, Weng L, Tang W, Jin S, Ma W . Myeloid-derived suppressor cells-new and exciting players in lung cancer. J Hematol Oncol. 2020; 13(1):10. PMC: 6995114. DOI: 10.1186/s13045-020-0843-1. View

12.

Ma P, Beatty P, McKolanis J, Brand R, Schoen R, Finn O . Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer. Front Immunol. 2019; 10:1401. PMC: 6594197. DOI: 10.3389/fimmu.2019.01401. View

13.

Jordan K, Amaria R, Ramirez O, Callihan E, Gao D, Borakove M . Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother. 2013; 62(11):1711-22. PMC: 4176615. DOI: 10.1007/s00262-013-1475-x. View

14.

Reilley M, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y . STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018; 6(1):119. PMC: 6240242. DOI: 10.1186/s40425-018-0436-5. View

15.

Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A . Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab. Clin Cancer Res. 2016; 22(23):5661-5672. DOI: 10.1158/1078-0432.CCR-15-3104. View

16.

Sinha P, Clements V, Fulton A, Ostrand-Rosenberg S . Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007; 67(9):4507-13. DOI: 10.1158/0008-5472.CAN-06-4174. View

17.

Kim H, Park S, Seo S, Jung I, Yoon H, Gabrilovich D . The Ratio of Peripheral Regulatory T Cells to Lox-1 Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer. Am J Respir Crit Care Med. 2018; 199(2):243-246. PMC: 6835091. DOI: 10.1164/rccm.201808-1502LE. View

18.

Chang C, Huang C . Poor dietary intake improved by total excision of oral cavity metastases in a patient with hepatocellular carcinoma and elevated myeloid-derived suppressor cells. Hepatobiliary Surg Nutr. 2020; 9(4):558-561. PMC: 7423536. DOI: 10.21037/hbsn.2020.03.21. View

19.

Lu L, Chang C, Hsu C . Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives. J Hepatocell Carcinoma. 2019; 6:71-84. PMC: 6511249. DOI: 10.2147/JHC.S159693. View

20.

Ostrand-Rosenberg S, Fenselau C . Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment. J Immunol. 2018; 200(2):422-431. PMC: 5765878. DOI: 10.4049/jimmunol.1701019. View